We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Product
Advertisement

Fast Antibody Production Services

Fast Antibody Production Services


Sino Biological has accumulated rich experience in the development and production of custom antibodies, providing high-quality antibody production services for pharmaceutical enterprises, research institutions, and diagnostic companies, supporting basic research, diagnostic reagent development, biological drug development, and other applications.

Sino Biological offers a variety of fast antibody production services, including fast mouse monoclonal antibody production, fast rabbit polyclonal antibody production, and beacon® antibody production service. Using optimized immunization protocols, Sino Biological has shortened the immunization period for the fast mouse mAb service from 8-12 to only 4-5 weeks, with the delivery of monoclonal antibodies as fast as 60 days. Fast rabbit polyclonal antibody production service completes the antibody production process from animal immunization to purified antibody within 45 days, delivers rabbit polyclonal antibodies with high ELISA titers (above 1:256,000). Beacon® single-cell platform obtains positive clones in as few as 35 days, providing you with fast, high-quality, and cost-effective antibody production.


About Sino Biological Inc
Sino Biological is an international reagent supplier and service provider. The company specializes in recombinant protein production and antibody development. All of Sino Biological's products are independently developed and produced, including recombinant proteins, antibodies and cDNA clones. Sino Biological is the researchers' one-stop technical services shop for the advanced technology platforms they need to make advancements. In addition, Sino Biological offers pharmaceutical companies and biotechnology firms pre-clinical production technology services for hundreds of monoclonal antibody drug candidates